JMP Securities Reiterates Market Outperform on Sagimet Biosciences, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Sagimet Biosciences (NASDAQ:SGMT) and maintained a $48 price target.
May 24, 2024 | 3:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Sagimet Biosciences (NASDAQ:SGMT) and maintained a $48 price target.
The reiteration of a Market Outperform rating and the maintenance of a $48 price target by JMP Securities is a positive signal for investors. It suggests confidence in the company's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100